Mandate Vinge assisted Cantargia in entering into a R&D agreement with Panorama Research

August 24, 2017

Cantargia AB (“Cantargia”) of Lund, Sweden, and Panorama Research Inc. (“Panorama”), a California based specialist antibody developer, have entered into a collaboration agreement to jointly accelerate Cantargia's second program directed towards autoimmune and inflammatory diseases. 

Cantargia’s proprietary antibodies, against the molecular target IL1RAP, will be affinity matured and humanized using Panorama’s proprietary technology. In addition, Panorama will generate cell lines optimized for high level GMP production. Cantargia will be responsible for subsequent down-stream development. Under the terms of the agreement, Panorama will share risk in the project in exchange for a fraction of future incomes from third parties or future sales.
 
Kristoffer Franzkeit advised Cantargia.

Sanctions round-up

Not long time ago sanctions were a rare occurrence which only involved obscure products and countries, and which were decided by the members of the United Nations Security Council. Today, the European Union and, in particular, the United States, impose sanctions and other trade restrictions with high frequency which have the potential to affect any type of transaction. Below you will find a summary of some recent developments.
December 22, 2020

EU Commission criticizes Sweden for its application of the rules on combined transports

Through a formal notice to Sweden, the European Commission has criticized the inadequate application of Directive 92/106/ECC on common rules for certain forms of combined transport of goods between Member States (the “Combined Transports Directive”). The notice mainly concerns the Swedish Transport Agency's application of the term "nearest suitable railway station"
December 11, 2020